课题基金 / 基金详情

Adjuvant Development within the context of a vaccine to protect against B. pertussis for use in newborns.

Adjuvant Development within the context of a vaccine to protect against B. pertussis for use in newborns.
在疫苗背景下开发佐剂,以预防新生儿感染百日咳博德特氏菌。
批准号:
10223090
负责人:
OFER LEVY
金额:
$372.16万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-09-30 至 2022-09-29

项目摘要

项目成果

OFER LEVY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This contract supports the development of an adjuvant through immunological characterization studies and compound optimization, up to and including IND-enabling studies. The main emphasis will be on testing and further development of the adjuvant for human licensure as a component of a licensed or investigational vaccine to protect against one or more non-HIV disease pathogens relevant to human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
  • 批准号:
    10435035
  • 项目类别:
  • 资助金额:
    $166.59万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10589826
  • 项目类别:
  • 资助金额:
    $22.79万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Project 3: In vitro modeling to define mechanisms of childhood vaccine response, susceptibility to respiratory infectious disease and asthma
  • 批准号:
    10435043
  • 项目类别:
  • 资助金额:
    $19.86万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
Immune development in early life (IDEAL) shapes vaccine response, respiratory infectious diseaseand asthma
  • 批准号:
    10589800
  • 项目类别:
  • 资助金额:
    $154.65万
  • 财政年份:
    2022
  • 负责人:
    OFER LEVY
  • 依托单位:
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: